Seek Labs Secures $3 Million for Oncology Research
The Salt Lake City biotech firm will use the funding to expand its CRISPR-based therapeutics platform into cancer treatment.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Should foundations prioritize funding experimental medical research to address gaps in current cancer treatments?
Seek Labs has entered a $3 million funding agreement with the Two2Ten Foundation to advance research into oncology. This capital will support the expansion of the company's proprietary Sequence Ablation Therapeutics platform.
Why it matters
The funding aims to accelerate the development of new cancer treatments specifically for patients who are currently underserved by existing medical options. The donation honors the memory of Travis Snyder.
The Sequence Ablation Therapeutics platform integrates computational sequence analysis with programmable CRISPR technology to target specific genetic sequences. The current oncology program remains in the preclinical research stage.
The players
Seek Labs
A Salt Lake City-based biotechnology firm focused on developing therapeutic platforms through computational sequence analysis and CRISPR.
Two2Ten Foundation
A charitable organization that provided the $3 million research grant to support oncology innovation in memory of Travis Snyder.
The details
Researchers at the Salt Lake City company will utilize the platform to evaluate therapeutic candidates within preclinical cancer models. The effort focuses on utilizing CRISPR technology to create targeted interventions for difficult-to-treat malignancies.
Timeline
October 26, 2026: Seek Labs announced the formal funding agreement.
The Tech Race
This development represents a strategic shift toward applying CRISPR gene-editing technology to address complex oncology challenges. It signals an effort to move beyond legacy small-molecule approaches by utilizing computational sequence analysis to achieve higher precision in therapeutic targeting.
This project could eventually lead to new therapeutic options for patients currently underserved by standard cancer treatments. While these technologies are currently in the preclinical stage, successful development may influence future clinical care standards.
The takeaway
The research findings will be shared through scientific presentations and journals to facilitate academic collaboration. The move underscores how private foundation backing can bridge the gap for early-stage preclinical biotech research.
Further reading
Learn more about the latest developments in the sector on our Biotech page.
Live Poll
Should foundations prioritize funding experimental medical research to address gaps in current cancer treatments?
